Publication list

 Peer reviewed publications

178.

K. Gotfryd, T. Boesen, J.S. Mortensen, G. Khelashvili, M. Quick, D.S. Terry, J.W. Missel, M.V. LeVine, P. Gourdon, S.C. Blanchard, J.A. Javitch, H. Weinstein, C.J. Loland, P. Nissen and U. Gether: X-ray structure of LeuT in an inward-facing occluded conformation reveals mechanism of substrate release.
Nature Communications (2020), in press

177.

N. Giguère, B. Delignat-Lavaud, F. Herborg, A. Voisin, Y. Li, V. Jacquemet, M. Anand-Srivastava, U. Gether, B. Giros and L.E. Trudeau.: Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout.
PLoS Genet (2019) 15(8):e1008352 [Epub ahead of print] 

176.

A.H. Runegaard, D. Dencker, G. Wörtwein and U. Gether: G protein-coupled receptor signaling in VTA dopaminergic neurons bidirectionally regulates the acute locomotor response to amphetamine but does not affect behavioral sensitization.
Neuropharmacology (2019) pii: S0028-3908(19)30209-6. [Epub ahead of print] 

175.

G.E. DiCarlo, J.I. Aguilar, H.J. Matthies, F.E. Harrison, K.E. Bundschuh, A. West, P. Hashemi, F. Herborg, M. Rickhag, H. Chen, U. Gether, M.T. Wallace and A Galli: Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors.
J Clin Invest (2019) 129, 3407-3419 

173.

A. Bay Kønig, C. Ciriachi, U. Gether and M Rickhag: Chemogenetic Targeting of Dorsomedial Direct-pathway Striatal Projection Neurons Selectively Elicits Rotational Behavior in Mice.
Neuroscience (2019) 401, 106-116

172.

A.H. Runegaard, C.M. Fitzpatrick, D.P.D. Woldbye, J.T. Andreasen A.T. Sørensen and U. Gether: Modulating Dopamine Signaling and Behavior with Chemogenetics: Concepts, Progress and Challenges.
Pharmacol Rev (2019) 71, 123-156

171.

S. Erlendsson, T.S Thorsen, G. Vauquelin, I. Ammendrup-Johnsen, V. Wirth, K.L. Martinez KL, K. Teilum, U. Gether and K.L. Madsen: Wirth, K.L. Martinez KL, K. Teilum, U. Gether and K.L. Madsen: Mechanisms of PDZ domain scaffold assembly illuminated by use of supported cell membrane sheets.
eLife (2019) Jan 3;8. pii: e39180

170.

C.M. Fitzpatrick, A.H. Runegaard, S.H. Christiansen, N.W. Hansen, S.H. Jørgensen, J.C. McGirr, A. de Diego Ajenjo, A.T. Sørensen, J.F. Perrier, A. Petersen, U. Gether, D.P.D. Woldbye and J.T. Andreasen: Differential effects of chemogenetic inhibition on dopamine and norepinephrine neurons in the mouse 5-choice serial reaction time task.
Prog Neuropsychopharmacol Biol Psychiatry (2018) 90, 264-276

169.

A.H. Runegaard, K.L. Jensen, G. Wortwein and U. Gether: Initial rewarding effects of cocaine and amphetamine assessed in a day using the single-exposure place preference protocol.
Eur J Neurosci (2018) [Epub ahead of print]

168.

A.H. Runegaard, A.T. Sørensen, C.M. Fitzpatrick, S.H. Jørgensen, A.V. Petersen, N.W. Hansen, P. Weikop, J.T. Andreasen, J.D. Mikkelsen, J.F. Perrier, D. Woldbye, M. Rickhag, G. Wortwein and U. Gether: Locomotor- and Reward-Enhancing Effects of Cocaine Are Differentially Regulated by Chemogenetic Stimulation of Gi-Signaling in Dopaminergic Neurons.
eNeuro (2018) Jun 11;5(3)

167.

K.L. Jensen, G. Sørensen, D. Dencker, W.A. Owens, T. Rahbek-Clemmensen, M. Brett Lever, A.H. Runegaard, N. Riis Christensen, P. Weikop, G. Wörtwein, A. Fink-Jensen, K.L. Madsen, L. Daws, U. Gether and M. Rickhag M.: PICK1-Deficient Mice Exhibit Impaired Response to Cocaine and Dysregulated Dopamine Homeostasis.
eNeuro (2018) Jun 18;5(3)

166.

F.P. Mayer, D. Schmid, W.A. Owens, G.G. Gould, M. Apuschkin, O. Kudlacek, I. Salzer, S. Boehm, P. Chiba, P.H. Williams, H.H. Wu, U. Gether, W. Koek, L.C. Daws and H.H. Sitte: An unsuspected role for organic cation transporter 3 in the actions of amphetamine.
Neuropsychopharmacology (2018) 43, 2408-2417

165.

R. Herlo, V.K. Lund, M.D. Lycas, A.M. Jansen, G. Khelashvili, R.C. Andersen, V.Bhatia, T.S. Pedersen, Pedro B.C. Albornoz, Niklaus Johner, Ina Ammendrup-Johnsen, Nikolaj Christensen, S.Erlendsson, M. Stoklund, J.B. Larsen, H. Weinstein, O. Kjærulff, D. Stamou, U. Gether and K.L. Madsen: An amphipathic helix directs cellular membrane curvature sensing and function of the BAR domain protein PICK1.
Cell Reports (2018) 23, 2056-2069

164.

P.S. Merkle PS, K. Gotfryd, M.A. Cuendet, K.Z. Leth-Espensen, U. Gether, C.J. Loland and K.D. Rand K.D.: Substrate-modulated unwinding of transmembrane helices in the NSS transporter LeuT.
Science Adv (2018) 4(5):eaar6179.

163.

F. Herborg, T.F. Andreassen, F. Berlin, C.J. Loland and U. Gether: Neuropsychiatric disease-associated dopamine transporter genetic variants display heterogeneous molecular phenotypes
J Biol Chem (2018) 293, 7250-7262 (selected for “JBC Recommended Reads”)

162.

K. L. Jensen, A.H. Runegaard, P. Weikop, U. Gether and M. Rickhag: Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake.
J Vis Exp (2017) Sep 21, 127

161.

T. Rahbek-Clemmensen, M.D. Lycas, S. Erlendsson, J. Eriksen, M. Apuschkin, F. Vilhardt, T. N. Jørgensen, F. H. Hansen and U. Gether: Super-resolution microscopy reveals functional organization of dopamine transporters into cholesterol and neuronal activity-dependent nanodomains.
Nature Communications (2017) 8, 740

160.

A.H. Runegaard, K.L. Jensen, D. Dencker, G. Wörtwein and U. Gether: Subjective perception of cocaine reward in mice assessed by a single exposure place preference (sePP) paradigm.
J Neurosci Methods (2017) 289, 85-92

159.

S.H. Jørgensen, C.M. Fitzpatrick, U. Gether, D. Woldbye and A.T. Sørensen: Chemogenetic Modulation of G Protein-Coupled Receptor Signalling in Visual Attention Research.
Basic Clin Pharmacol Toxicol. (2017) 121, 373-38

158.

S.E. Jacobsen, U. Gether, and H. Bräuner-Osborne: Investigating the molecular mechanism of positive and negative allosteric modulators in the calcium-sensing receptor dimer.
Scientific Reports (2017) 7, 46355

157.

S.E. Jacobsen, I. Ammendrup-Johnsen, A.M. Jansen, U. Gether, K.L. Madsen and H. Bräuner-Osborne: The GPRC6A Receptor displays Constitutive Internalization and Sorting to the Slow Recycling Pathway.
J Biol Chem. (2017) 292, 6910-6926

156.

S. Erlendsson, K. Gotfryd, F.H. Larsen, J.S. Mortensen, M.A. Geiger, B.J. van Rossum, H. Oschkinat, U. Gether, K. Teilum, C.J. Loland: Direct assessment of substrate binding to the Neurotransmitter:Sodium Symporter LeuT by solid state NMR.
Elife (2017) Jan 24;6. pii: e19314

155.

C. M. Fitzpatrick, M. Caballero-Puntiverio, U. Gether, T. Habekost, C. Bundesen, S. Vangkilde, D. P. Woldbye, J.T. Andreasen and A. Petersen A.: Theory of Visual Attention (TVA) applied to mice in the 5-choice serial reaction time task.
Psychopharmacology (2017) 234, 845-855

154.

A. Sohail, K. Jayaraman, S. Venkatesan, K. Gotfryd, M. Daerr, U. Gether, U, C.J. Loland, K.T. Wanner, M. Freissmuth, H.H. Sitte, W. Sandtner, and T. Stockner: The Environment Shapes the Inner Vestibule of LeuT.
PLoS Comput Biol. (2016) 12, e1005197.

153.

C. Billesbølle, J. Mortensen, A. Sohail, S. Schmidt, L. Shi, H.H. Sitte, U. Gether and C.J. Loland: Transition metal ion FRET uncovers K+ regulation of a neurotransmitter:sodium symporter
Nature Communications (2016) 7, 12755.

152.

A.H. Runegaard, K.L. Jensen, C.M. Fitzpatrick, D. Dencker, P. Weikop, U. Gether and Rickhag M.: Preserved dopaminergic homeostasis and dopamine-related behaviour in hemizygous TH-Cre mice.
Eur J Neurosci (2017) 45, 121-128

151.

G. Khelashvili, S.G. Schmidt, L. Shi, J.A. Javitch, U. Gether, C.J. Loland, H. Weinstein: Conformational dynamics on the extracellular side of LeuT controlled by Na+ and K+ ions and the protonation state of E290.
J Biol Chem (2016) 291,19786-19799

150.

M. Caron and U. Gether: Structural biology: Antidepressants at work.
Nature (2016) 532, 320-321

149.

A. Vuorenpää, I. Ammendrup-Johnsen, T.N. Jørgensen and U. Gether: A kinome wide screen identifies novel kinases involved in regulation of monoamine transporter function.
Neurochem Int (2016) 98,103-114

148.

A. Vuorenpää, T.N. Jørgensen, A.H. Newman, K.L. Madsen, M. Scheinin and U. Gether: Differential internalization rates and postendocytic sorting of the norepinephrine and dopamine transporters are controlled by structural elements in the N-termini.
J Biol Chem (2016) 291, 5634-5651

147.

U. Knorr, P. Koefoed, C. Gluud, J. Wetterslev, P. Winkel, U. Gether, M. Vinberg, and L.V. Kessing: Effect of escitalopram versus placebo on GRα messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression - a secondary outcome analysis from the randomized AGENDA trial.
Nord J Psychiatry (2016) 70, 297-302

146.

M.A. Larsen, P. Plenge,  J. Andersen, J.N. Eildal, A.S.Kristensen, K.P. Bøgesø, U. Gether, K. Strømgaard, B. Bang-Andersen, C.J. Loland: Structure-activity relationship studies of citalopram derivatives: examining substituents conferring selectivity for the allosteric site in the serotonin transporter.
Br J Pharmacol. (2016) 173, 925-936

145.

U. Knorr, P. Koefoed, M.H. Soendergaard, M. Vinberg, U. Gether, C. Gluud, J. Wetterslev, P. Winkel and L.V. KessingNo effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial.
Acta Neuropsychiatr. (2016) 28,101-109

144.

C.B. Billesbølle, M.B. Krüger, L. Shi, M. Quick, Z.Li, S. Stolzenberg, J. Kniazeff, K. Gotfryd, J. S. Mortensen, J.A. Javitch, H. Weinstein, C.J. Loland and U. Gether: Substrate-induced unlocking of the inner gate determines the catalytic efficiency of a neurotransmitter:sodium symporter.
J Biol Chem (2015) 290, 26725-38

143.

T.M. Axelsen, C.A. Navntoft, S.H. Christiansen, J. K Dreyer, J.B. Sørensen, U. Gether U and D.P. Woldbye: Optogenetics brings hidden neural mechanisms into the light and could become a future therapy.
Ugeskr Laeger (2015) 177(34)

142.

M. Apuschkin, S. Stilling, T. Rahbek-Clemmensen, G. Sørensen, G. Fortin, F. Herborg Hansen, J. Eriksen, L.E. Trudeau, K. Egerod, U. Gether, M. Rickhag: A novel dopamine transporter transgenic mouse line for identification and purification of midbrain dopaminergic neurons reveals midbrain heterogeneity.
Eur J Neurosci (2015) 42, 2438-2454

141.

M.L. Karlsen1, T.S. Thorsen, N. Johner, I. Ammendrup-Johnsen, S. Erlendsson, X. Tian, J.B. Simonsen, R. Høiberg-Nielsen, N.M. Christensen, G. Khelashvili, W. Streicher, K. Teilum, B. Vestergaard, H. Weinstein, U. Gether, L. Arleth and K.L. Madsen: Structure of dimeric and tetrameric complexes of the BAR domain protein PICK1 determined by small-angle X-ray scattering.
Structure (2015) 23, 1258-1270

140.

T. Steinkellner, T. Montgomery, T. Hofmaier, O. Kudlacek, J.-W. Yang, M. Rickhag, G. Jung, G. Lubec, U. Gether, M. Freissmuth and Harald Sitte: Amphetamine action at the cocaine- and antidepressant sensitive serotonin transporter is modulated by αCaMKII.
J Neurosci (2015) 35, 8258-8271

139.

S. Stolzenberg, M. Quick, C. Zhao, K. Gotfryd, G. Khelashvili, U. Gether, C.J. Loland, J.A. Javitch, S. Noskov, H. Weinstein and L. Shi: Mechanism of the association between Na+ binding and conformations at the intracellular gate in Neurotransmitter:Sodium Symporters.
J Biol Chem (2015) 290, 13992-134003

138.

E. Cartier, P.J. Hamilton, A.N. Belovich A. Shekar, N.G. Campbell, C. Saunders, T.F. Andreassen, U. Gether, J. Veenstra-Vanderweele, J.S. Sutcliffe, P.G. Ulery-Reynolds, K. Erreger, H.J. Matthies and A.  Galli: Rare autism-associated variants implicate syntaxin 1 (STX1 R26Q) phosphorylation and the dopamine transporter (hDAT R51W) in dopamine neurotransmission and behaviors.
EBioMedicine (2015) 2, 135-146

137.

J. Rajamanickam, B. Annamalai, T. Rahbek-Clemmensen, S. Sundaramurthy, U. Gether, L.D. Jayanthi and S. Ramamoorthy: Akt-Mediated regulation of antidepressant-sensitive serotonin transporter function, cell surface expression and phosphorylation.
Biochem J (2015) 468, 177-90

136.

P.S. Pinheiro, A.M. Jansen, H. de Wit, B. Tawfik, K.L. Madsen, M. Verhage, U. Gether and J.B. Sørensen: The BAR Domain Protein PICK1 Controls Vesicle Number and Size in Adrenal Chromaffin Cells.
J Neurosci (2014) 34, 10688-10700

135.

T. Rahbek-Clemmensen, T. Bay, J. Eriksen, U. Gether and T.N. Jørgensen: The serotonin transporter undergoes constitutive internalization and is primarily sorted to late endosomes and lysosomal degradation.
J Biol Chem (2014) 289, 23004-19

134.

S. Erlendsson, M. Rathje, P.O. Heidarsson, F.M. Poulsen, K.L. Madsen, K. Teilum and U. Gether: PICK1 (protein interacting with C-kinase 1) binding promiscuity relies on unconventional PDZ (PSD-95/Discs-large/ZO-1 homology) binding modes for non-class II PDZ ligands.
J Biol Chem (2014) 289, 25327-40

133.

L. Borre, T.F. Andreassen, L. Shi, H. Weinstei and U. Gether. The second sodium site in the dopamine transporter controls cation permeability and is regulated by chloride.
J Biol Chem (2014) 289, 25764-73

132.

V. Kumar, T. Rahbek-Clemmensen, C.B. Billesbølle, T.N. Jorgensen, U. Gether and A.H. Newman: Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram.
ACS Med Chem Lett (2014) 5, 696-699

131.

F.H. Hansen, T. Skjørringe, S. Yasmeen, N.V. Arends, M.A. Sahai, K. Erreger, T. F. Andreassen, M. Holy, P.J. Hamilton, V. Neergheen, M. Karlsborg, A.H. Newman, S. Pope, S. JR. Heales, L. Friberg, I. Law, L.H. Pinborg, H.H. Sitte, C. Loland, L. Shi, H. Weinstein, A. Galli, L.E. Hjermind, L.B. Møller and U. Gether: Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.
J Clin Invest (2014) 124, 3107-20

130.

T. Steinkellner, L. Mus, B. Eisenrauch, A. Constantinescu, D. Leo, L. Konrad, M. Rickhag, G. Sørensen , E.V. Efimova, E. Kong, M. Willeit, T.D. Sotnikova, O. Kudlacek, U. Gether, M. Freissmuth, D.D. Pollak, R.R. Gainetdinov and H,H, Sitte: In vivo Amphetamine Action is Contingent on αCaMKII.
Neuropsychopharmacology. (2014) 39, 2681-93

129.

T. N. Jørgensen, P.M. Christensen and U. Gether: Serotonin-induced down-regulation of cell surface serotonin transporter.
Neurochem Int. (2014) 73,107-12

128.

P.S. Chae, A.C. Kruse, K. Gotfryd, R.R. Rana, K.H. Cho, S.G. Rasmussen, H.E. Bae, R. Chandra, U. Gether, L. Guan, B.K. Kobilka, C. J. Loland, B. Byrne and S.H. Gellman: Novel Tripod Amphiphiles for Membrane Protein Analysis.
Chemistry (2013) 19, 15645-51

127.

P.J. Hamilton, N.G. Campbell, S. Sharma, K. Erreger, F. Herborg Hansen, C. Saunders, A.N. Belovich, NIH ARRA Autism Sequencing Consortium, M.A. Sahai, E.H. Cook, U. Gether, H.S. McHaourab, H.J. Matthies, J.S. Sutcliffe and A. Galli: De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder.
Mol Psychiatry (2013) 18, 1315-1323

126.

M. Rathje, H. Fang, J.L. Bachman, V. Anggono, U. Gether, R.L. Huganir, K.L. Madsen: AMPA receptor pHluorin-GluA2 reports NMDA receptor-induced intracellular acidification in hippocampal neurons.
Proc Natl Acad Sci U S A (2013) 110, 14426-14431

125.

M. Rickhag, W. A. Owens, M.T. Winkler, K. N. Strandfelt, M. Rathje, G. Sørensen, B. Andresen, K.L. Madsen, T.N. Jørgensen, G. Wörtwein, D.P. Woldbye, H. H. Sitte, L.C. Daws and U. Gether: Membrane-permeable C-terminal dopamine transporter peptides attenuate amphetamine-evoked dopamine release.
J Biol Chem (2013) 288, 27534-27544. Selected as ‘Paper of the week’ Oct 2013

124.

M.H. Larsen, A. Albrechtsen, L.W. Thørner, T. Werge, T. Hansen, U. Gether, E. Haastrup and  H. Ullum: Genome-Wide Association Study of Genetic Variants in LPS-Stimulated IL-6, IL-8, IL-10, IL-1ra and TNF-α Cytokine Response in a Danish Cohort.
PLoS One. (2013) 8:e66262

123.

B. Holst, K. L. Madsen, A. M. Jansen, C. Jin, M. Rickhag, V. K. Lund, M. Jensen, V. Bhatia, G. Sørensen, A. N. Madsen, Z. Xue, S. K. Møller, D. P.D. Woldbye, K. Qvortrup, R. Huganir, D. Stamou, O. Kjærulff and U. Gether: PICK1-Deficiency Impairs Secretory Vesicle Biogenesis and Leads to Growth Retardation and Decreased Glucose Tolerance.
PLOS Biology  (2013) 11:e1001542

122.

M. Rickhag, F. Herborg Hansen, G. Sørensen, K. Nørgaard Strandfelt, B. Andresen, K. Gotfryd, K. L. Madsen, I. Vestergaard-Klewe, I.n Ammendrup-Johnsen, J. Eriksen, A. H. Newman, E.-M. Füchtbauer, J. Gomeza, D. P. D. Woldbye, G Wörtwein and U. Gether: A C-terminal PDZ domain-binding sequence is required for striatal distribution of the dopamine transporter.
Nature Communications (2013) 4, 1580

121.

P.S. Chae, R. R. Rana, K. Gotfryd, S. G. Rasmussen, A. C. Kruse, K. H. Cho, S. Capaldi, E. Carlsson, B.K. Kobilka, C. J. Loland, U. Gether, S. Banerjee, B. Byrne, L. K. Lee and S. H. Gellman: Glucose-Neopentyl Glycol (GNG) amphiphiles for membrane protein study.
Chem Commun (Camb). (2013) 49, 2287-2289

120.

K.J. Simmons, K. Gotfryd, C. .B. Billesbølle, C. J. Loland, U. Gether, C.W. Fishwick, A.P. Johnson: A virtual high-throughput screening approach to the discovery of novel inhibitors of the bacterial leucine transporter, LeuT.
Mol Membr Biol. (2013) 30, 184-189

119.

P. Plenge, L. Shi, T. Beuming, A. H. Newman, H. Weinstein, U. Gether and C. J. Loland: The allosteric binding site for antidepressants in the serotonin transporter is located to the conserved extracellular vestibule.
J Biol Chem. (2012) 287, 39316-39326

118.

S. Bröer and U. Gether: The solute carrier family 6.
Br J Pharmacol (2012) 167, 256-278.

117.

U. Knorr, M. Vinberg, U. Gether, P. Winkel, C. Gluud, J. Wetterslev, L.V. Kessing: The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial.
Psychiatry Res. (2012) 200, 354-360

116.

P.S. Chae, S. G. Rasmussen, R. R. Rana, K. Gotfryd, A. C. Kruse, A. Manglik, K. H. Cho, S. Nurva, U.  Gether, L. Guan, C. J. Loland, B. Byrne, B. K. Kobilka and S. H. Gellman: A new class of amphiphiles bearing rigid hydrophobic groups for solubilization and stabilization of membrane proteins.
Chemistry (2012) 18, 9485-9490

115.

U. Knorr, M. Vinberg, E.L. Mortensen, P. Winkel, C. Gluud, J. Wetterslev and U. Gether: Effect of chronic escitalopram versus placebo on personality traits in healthy first-degree relatives of patients with depression: a randomized trial.
PloS One (2012) 7, e31980

114.

K. L. Madsen, T. S. Thorsen, T. Rahbek-Clemmensen, J. Eriksen and U. Gether: Protein Interacting with C Kinase 1 (PICK1) Reduces Reinsertion Rates of Interaction Partners Sorted to the RAB11-Dependent Slow Recycling Pathway.
J Biol Chem 2012 287, 12293-308

113.

I. Ammendrup-Johnsen, T. S. Thorsen, U. Gether and K. L. Madsen.: Serine 77 in the PDZ Domain of PICK1 Is a Protein Kinase Cα Phosphorylation Site Regulated by Lipid Membrane Binding.
Biochemistry (2012) 51, 586-96

112.

S.H. Vaz, T. N. Jorgensen, S. Cristovao-Ferreira, S. Duflot, J. A. Ribeiro, U. Gether, A. M. Sebastiao: Brain-derived neurotrophic factor (BDNF) enhances GABA transport by modulating the trafficking of GABA transporter-1 (GAT-1) from the plasma membrane of rat cortical astrocytes.
J Biol Chem (2011) 286, 40464-76

111.

A. S. Kristensen, J. Andersen, T. N. Jørgensen, L. Sørensen, J. Eriksen, C. J. Loland, K. Strømgaard and U. Gether: The SLC6 neurotransmitter transporters: Structure, function, and regulation.
Pharmacological Reviews (2011) 63, 585-640

110.

L. Olsen, T. Hansen, S. Djurovic, E. Haastrup, A. Albrecthsen, L. K. Hoeffding, A. Secher, O. Gustafsson, K. D. Jakobsen, F. C. Nielsen, H. Ullum, G. Morken, I. Agartz, I. Melle, U. Gether, O. A. Andreassen and Werge T: The Copy number variations in affective disorders and meta-analysis.
Psychiatr Genet (2011) 21, 319-322

109.

U. Knorr, M. Vinberg, A. Hansen, M. Klose, U. Feldt-Rasmussen, L. Hilsted, J. Hasselstrøm, U. Gether, P. Winkel, C. Gluud, J. Wetterslev, L.V. Kessing: Escitalopram and neuroendocrine response in healthy first-degree relatives to depressed patients - a randomized placebo-controlled trial.
PLoS One (2011) 6(6), e21224.

108.

T. S. Thorsen, K. L. Madsen, T. Dyhring, A. Bach, D. Peters, K. Strømgaard, L. C. B. Rønn and U. Gether: A Fluorescence Polarization Based Screening Assay for Identification of Small Molecule Inhibitors of the PICK1 PDZ Domain.
Combinatorial Chemistry & High Throughput Screening (2011) 14, 590-600

107.

H. Bisgaard, M. Andreas B. Larsen, S. Mazier, T. Beuming, A. H. Newman, H. Weinstein, L. Shi, C. J. Loland and U. Gether: The binding sites for benztropines and dopamine in the dopamine transporter overlap.
Neuropharmacology (2011) 60, 182-190

106.

P. S. Chae,  K. Gotfryd, J. Pacyna, L. J. Miercke, S. G. Rasmussen, R. A. Robbins, R. R. Rana, C. J. Loland, B. Kobilka, R. Stroud, B. Byrne, U. Gether, S. H. Gellman: Tandem facial amphiphiles for membrane protein stabilization.
J Am Chem Soc. (2010) 132, 16750-16752

105.

P. Seok Chae, S. G. F. Rasmussen, R.  Rana, K. Gotfryd, R. Chandra, M. A. Goren,A. C. Kruse, S. Nurva, C. J. Loland, Y. Pierre, D. Drew, J. L. Popot, D. Picot, B. G. Fox, L. Guan, U. Gether, B., B. Kobilka and S. H. Gellman: Accessible new amphiphiles for solubilization, stabilization and crystallization of membrane proteins.
Nature Methods (2010) 7, 1003-1008

104.

A. Bach, N. Stuhr-Hansen, T.S. Thorsen, N. Bork, I. S. Moreira, K. Frydenvang, S. Padrah, S. B. Christensen, K. L. Madsen, H. Weinstein, U. Gether and K. Strømgaard: Structure-activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1.
Org Biomol Chem. (2010) 8, 4281-4288

103.

J. D. Bukh, C. Bock, M. Vinberg, U. Gether and L. V. Kessing: Clinical utility of Standardised Assessment of Personality - Abbreviated Scale (SAPAS) among patients with first episode depression.
J Affect Disord (2010) 127, 199-202

102.

J. Eriksen, W. E. Bjørn-Yoshimoto, T. N. Jørgensen, A. H.Newman and U. Gether: Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and dopaminergic neurons.
J Biol Chem (2010) 285, 27289-27301

101.

J. Mollenhauer, D. Stamou, A. Flyvbjerg, J. Wengel, U. Gether  J. Kjems, T. Bjørnholm and F. Besenbacher: David versus Goliath.
Nanomedicine (2010) 6,504-509

100.

J.D. Bukh,  C. Bock, M. Vinberg, U. Gether and L.V. Kessing: Gender differences among patients with a single depressive episode.
Psychopathology (2010) 43, 59-169

99.

C. Bock, J.D. Bukh, M. Vinberg, U. Gether and L.V. Kessing: The influence of comorbid personality disorder and neuroticism on treatment outcome in first episode depression.
Psychopathology (2010) 43, 197-204

98.

K. L. Madsen, V. K. Bhatia, U. Gether, D. Stamou: BAR domains, amphipathic helices and membrane-anchored proteins use the same mechanism to sense membrane curvature.
FEBS Lett (2010) 584, 1848-1855

97.

S. Sucic, S. Dallinger, B. Zdrazil, R. Weissensteiner, T. N. JørgensenN, M. Holy, O. Kudlacek, S Seidel, J. H. Cha, U. Gether, A.H. Newman, G. F. Ecker, M. Freissmuth, H.H.Sitte: The amino terminus of monoamine transporters is a lever required for the action of amphetamines.
J Biol Chem (2010) 285, 10924-38

96.

J. Eriksen, T. N. Jørgensen and U. Gether: Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges (review).
J. Neurochemistry (2010) 113, 27-41.

95.

T. S. Thorsen, K. L. Madsen, N. Rebola, M. Rathje, V. Anggono, A. Bach, I. S. Moreira, N. Stuhr-Hansen, T. Dyhring, D. Peters, T. Beuming, R. Huganir, H. Weinstein, C. Mulle, K. Strømgaard, L. C. Rønn and U. Gether: Identification of a small molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD
Proc Natl Acad Sci U S A  (2010) 107, 413-418

94.

J. D. Bukh, C. Bock, M. Vinberg, T. Werge, U. Gether, L. V. Kessing: No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment.
Eur Neuropsychopharmacol (2009) 20, 327-335

93.

V. Bhatia, K. Madsen , P.Y. Bolinger, A. Kunding, P. Hedegaard , U. Gether and D. Stamou: Amphipathic motifs in BAR domains are essential for membrane curvature sensing.
EMBO J (2009) 28, 3303-3314

92.

A. M. Jansen, D. R. Nässel  K. L. Madsen A. G. Jung, U. Gether, O. Kjaerulff O.: PICK1 expression in the Drosophila central nervous system primarily occurs in the neuroendocrine system.
J Comp Neurol (2009) 517, 313-332

91.

N. S. Hatzakisa, V. K. Bhatiaa, J. Larsen, K. L. Madsen, P. Bolinger, A. H. Kunding, J. Castillo, U. Gether, P. Hedegård and D. Stamou: How curved membranes recognize amphipathic helices and protein anchoring motifs.
Nature Chem Biol (2009) 5, 835-841

90.

T. N. Rasmussen, P. Plenge, T. Bay, J. Egebjerg. and U. Gether: A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation.
Neuropharmacology (2009) 57, 287-294

89.

J. Eriksen, S. G. F. Rasmussen, T .N. Rasmussen, C. Bjerggaard Vaegter, J. H. Cha, M. Zou, A. H. Newman and U. Gether: Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogues.
J. Neuroscience (2009) 29, 6794-6808

88.

A.K. Meinild, D.D. Loo, S. Skovstru, U. Gether and N. MacAulay: Elucidating conformational changes in the gamma-aminobutyric acid (GABA)-transporter-1.
J Biol Chem (2009) 284, 16226-16235

87.

U. Knorr, M. Vinberg, M. Klose,  U. Feldt-Rasmussen, L. Hilsted, A. Gade, E. Haastrup, O. Paulson, J. Wetterslev, C. Gluud, U. Gether, L. V. Kessing: Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression.
Trials (2009) 10, 66

86.

L. V. Kessing, J. D. Bukh, C. Bock, M. Vinberg and U. Gether: Does bereavement-related first episode depression differ from other kinds of first depressions?
Soc Psychiatry Psychiatr Epidemiol (2010) 45, 801-808

85.

J. D Bukh, C. Bock, M. Vinberg, T. Werge and U. Gether and Vedel Kessing L.: Interaction between genetic polymorphisms and stressful life events in first episode depression.
J Affect Disord (2009) 119, 107-115

84.

C. Bock, J.D. Bukh, M. Vinberg, U. Gether and Kessing LV.: Validity of the diagnosis of a single depressive episode in a case register.
Clin Pract Epidemol Ment Health (2009) 5, 4

83.

C. Bock, J.D. Bukh, M. Vinberg, U. Gether and L.V. Kessing LV.: Do stressful life events predict medical treatment outcome in first episode of depression?
Soc Psychiatry Psychiatr Epidemiol (2009) 44. 752-760

82.

T.T. Lu, O. Lao, M. Nothnagel, O. Junge, S. Freitag-Wolf, A. Caliebe, M. Balascakova, J. Bertranpetit, L.A. Bindoff, D. Comas, G. Holmlund, A. Kouvatsi, M. Macek, I. Mollet, F. Nielsen, W. Parson, J. Palo, R. Ploski, A. Sajantila, A. Tagliabracci, U. Gether, T. Werge, F. Rivadeneira, F, Hofman A, Uitterlinden AG, Gieger C, Wichmann HE, Ruether A, Schreiber S, Becker C, P. Nürnberg P, M.R. Nelson, M. Kayser and M. Krawczak: An evaluation of the genetic-matched pair study design using genome-wide SNP data from the European population.
Eur J Hum Genet (2009) 17, 967-975

81.

O. Lao, T.T. Lu, M. Nothnagel, O. Junge, S. Freitag-Wolf, A. Caliebe, M. Balascakova, J. Bertranpetit, L.A. Bindoff, D. Comas, G. Holmlund, A. Kouvatsi, M. Macek, I. Mollet, W. Parson, J. Palo, R. Ploski, A Sajantila, A. Tagliabracci, U. Gether, T. Werge, F. Rivadeneira, A. Hofman , A.G. Uitterlinden, C. Gieger, H.E. Wichmann, A. Rüther, S. Schreiber, C. Becker, P. Nürnberg, M.R. Nelson, M. Krawczak and M. Kayser: Correlation between genetic and geographic structure in Europe.
Curr Biol (2008) 18, 1241-1248

80.

F. Binda, C. Dipace, E. Bowton, D. S. Robertson, B.J. Lute, J.U. Fog, M. Zhang, N. Sen, R.J. Colbran, M.E Gnegy, U. Gether, J.A Javitch, K. Erreger, A. Galli: Syntaxin1A Interaction with the dopamine transporter promotes amphetamine-Induced Dopamine Efflux.
Mol Pharmacol (2008) 74, 1101-1108

79.

T. Beuming, J. Kniazeff, M. L. Bergmann, L. Shi, L. Gracia, K. Raniszewska, A. H.Newman, J. A. Javitch, H. Weinstein, U. Gether*, and C. J. Loland: The dopamine and cocaine binding site in the dopamine transporter are overlapping.
Nature Neuroscience (2008) 11, 780-789 *corresponding author

78.

K. L. Madsen, J. Eriksen, L. Milan-Lobo, D. Han, U. Henriksen, V. Bhatia, D. Stamou, H. H. Sitte, H. T. McMahon, H A. Weinstein and U. Gether: Membrane localization is necessary and sufficient for activation of the PICK1 BAR (Bin/amphyphysin/Rvs) domain.
Traffic (2008) 9, 1327-1343

77.

J. Kniazeff, L. Shi, C. J. Loland, J. A. Javitch, H. Weinstein and U. Gether: A conserved intracellular ionic network regulates conformational transitions in the dopamine transporter.
J Biol Chem  (2008) 283, 17691-701

76.

I,V, Klewe, S.M. Nielsen, L. Tarpø, E. Urizar, C. Dipace, J.A. Javitch, U. Gether, J. Egebjerg, K.V. Christensen: Recruitment of beta-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling.
Neuropharmacology (2008) 54, 1215-1222

75.

I. Bartholomaeus, L. Milan-Lobo, A. Nicke,  S. Dutertre, H. Hastrup, A. Jha, U. Gether, H.H. Sitte, H. Betz H, V. Eulenburg: Glycine transporter dimers: Evidence for occurrence in the plasma membrane.
J Biol Chem (2008) 18, 10978-10991

74.

C.J. Loland, R. I. Desaib, M. Zouc, J. Caoc, P. Grundtc, K. Gerstbreind, H. H. Sitte, A. H. Newman, J. L. Katz and U. Gether: Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors.
Mol Pharmacol (2008) 73, 813-23

73.

M.  Bassan, H. Liu, K. L. Madsen, J. Zhou, W. Chen, M. A. Brasch, J. Staudinger, T. DeSilva, U. Gether, N. Irwin and P. A. Rosenberg: Interaction Between the Glutamate Transporter GLT1b and the Synaptic PDZ Domain Protein PICK1.
Eur J Neuroscience (2008)1, 66-82

72.

E. M. Adkins, J. U. Fog, J. Eriksen, D. J. Samuvel, L. D. Jayanthi, C. Bjerggaard Vaegter, S.Ramamoorthy and U. Gether: Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching.
Biochemistry (2007) 46,10484-10497

71.

P. Plenge, U. Gether and S. G. Rasmussen 2: Allosteric effects of R- and S-citalopram on the human serotonin transporter: Evidence for distinct high- and low-affinity binding sites.
Eur J. Pharmacol (2007) 567.1-9

70.

J. U. Fog, H. Khoshbouei, M. Holy, W. Owens, C. B. Vaegter, N. Sen, Y. Nikandrova, D.G. McMahon, R. J. Colbran, L. C. Daws, H. H. Sitte, J. A. Javitch, A. Galli and U. Gether: Calmodulin kinase II interacts with the dopamine transporter C-terminus to regulate amphetamine-induced reverse transport.
Neuron (2006) 51, 417-429

69.

U. Gether, P. H. Andersen, O. M. Larsson, and A. Schousboe: Neurotransmitter Transporters: Molecular function of important drug targets.
Trends Pharmacol Sci (2006) 27, 375-383.

68.

K.M. Kahlig, B.J.Lute, Y. Wei, C.J. Loland, U. Gether, J.A. Javitch and A. Galli: Regulation of Dopamine Transporter Trafficking by Intracellular Amphetamine.
Mol Pharmacol (2006) 70, 542-548

67.

L.D. Jayanthi, B. Annamalai, D.J. Samuvel, U. Gether and S. Ramamoorthy. Phosphorylation of the norepinephrine transporter at threonine 258 and serine 259 is linked to protein kinase C-mediated transporter internalization.
J Biol Chem (2006) 281, 23326-23340

66.

C. Martinat, J.J. Bacci, T. Leete, J. Kim, WB Vanti, A.H. Newman, J.H. Cha, U. Gether, H. Wang and A. Abeliovich: Cooperative transcription activation by Nurr1 and  itx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype.
Proc Natl Acad Sci U S A (2006) 103, 2874-2879

65.

J. H. Cha, M. Zou, E. M. Adkins, S. G. F. Rasmussen, C. J. Loland, B. Schonenberger, U. Gether and A. H. Newman: Rhodamine Labeled - 2-carbomethoxy-3-(3,4-dichlorophenyl)tropane Analogues as High Affinity Fluorescent Probes for the Dopamine Transporter.
J Med Chem (2005) 48, 7513-7516

64.

J. Kniazeff, C. J. Loland, N. Goldberg, M. Quick, S. Das, H. H. Sitte, J. A. Javitch and U. Gether: Intramolecular cross-linking in a bacterial homolog of mammalian SLC6 neurotransmitter transporters suggests an evolutionary conserved role of transmembrane segments 7 and 8.
Neuropharmacology, (2005) 49,715-723

63.

U. Henriksen, Jacob U. Fog., T. Litman and U. Gether: Identification of intra- and intermolecular disulfidebridges in the multidrug resistance transporter ABCG2.
J Biol Chem (2005) 280, 36926-36934

62.

K.L. Madsen, T. Beuming, M.Y. Niv, V. Chang, K.K. Dev, H. Weinstein and U. Gether: Molecular determinants for the complex binding specificity of the PDZ domain in PICK1.
J Biol Chem (2005) 280, 20539-20548

61.

U. Henriksen, U. Gether, and T. Litman: Effect of Walker A mutation (K86M) in the multidrug ATP-binding cassette half-transporter ABCG2 on dimerization and surface targeting in HEK293 cells.
J Cell Sci (2005) 118, 1417-1426

60.

S.G.F. Rasmussen and U. Gether: Purification and fluorescent labeling of the human serotonin transporter.
Biochemistry (2005) 44, 3494-3505

59.

A.K. Meinild, H.H. Sitte and U. Gether: Zn2+ induces an uncoupled anion flux in the dopamine transporter.
J Biol Chem (2004), 279, 49671-49679

58.

C. Bjerggaard, J. Fog, K. Madsen, H. Hastrup, J. Javitch and U. Gether: Surface targeting of the dopamine transporter involves discrete epitopes in the distal carboxyterminus but occurs independently of PDZ domain interactions.
J Neuroscience (2004) 24, 7024-7036

57.

C.J. Loland C. Granas, J.A. Javitch and U. Gether: Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding.
J Biol Chem (2004) 279, 3228-3238

56.

S.G.F. Rasmussen, E. Adkins and U. Gether: Structural and functional probing of the biogenic amine transporters by fluorescence spectroscopy (review).
Eur. J. Pharmacol. (2003) 479, 13-22

55.

C.J. Loland, Kristine Nørgaard-Nielsen and U. Gether: Probing dopamine transporter structure and function by Zn2+-site engineering (review).
Eur J Pharmacol
(2003) 479, 187-197

54.

L. Norregaard, C.J. Loland, and U. Gether: Evidence for distinct sodium, dopamine and cocaine dependent conformational changes in TM7 and TM8 of the dopamine transporter.
J Biol Chem (2003) 278, 30587-96

53.

N. MacAulay, A.K. Meinild, T. Zeuthen, U. Gether: Residues in the extracellular loop 4 are critical for maintaining the conformational equilibrium of the gamma -aminobutyric acid (GABA) transporter-1.
J Biol Chem (2003) 278, 28771-7

52.

C. Granas, J. Ferrer, C.J. Loland, J.A. Javitch and U. Gether: N-terminal phosphorylation occurs independently of transporter internalization.
J Biol Chem (2003) 278, 4990-5000

51.

U. Gether, F. Asmar, A.K. Meinild and S.G. Rasmussen: Structural basis for activation of G-protein-coupled receptors.
Pharmacol Toxicol (2002) 91(6):304-12

50.

N. MacAulay, T. Zeuthen and U. Gether: Conformational basis for the Li+-induced leak current in the -aminobutyric acid (GABA) transporter-1.
J Physiol (2002) 544,447-58

49.

MacAulay N, Gether U, Klaerke DA, Zeuthen T.: Passive water and urea permeability of a human Na(+)-glutamate cotransporter expressed in Xenopus oocytes.
J Physiol (2002) 542,817-828

48.

K. Nørgaard-Nielsen, L. Norregaard, H. Hastrup, J.A. Javitch and U. Gether: Zn2+ site engineering at the oligomeric interface of the dopamine transporter.
FEBS Letter (2002) 524, 87-91

47.

P. Scholze, L. Norregaard, E.A. Singer, M. Freissmuth, U. Gether, H.H. Sitte: The role of zinc ions in reverse transport mediated by monoamine transporters.
J Biol Chem (2002) 277, 21505-13

46.

C.J. Loland, L. Norregaard and U. Gether: Generation of an activating Zn2+ switch in the dopamine transporter: Mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle.
Proc Natl Acad Sci U S A  (2002) 99, 1683-8

45.

U. Gether and B. K. Kobilka: Use of fluorescence spectroscopy to study conformational changes in the 2-adrenoceptor.
Methods Enzymol.(2002) 343,170-82

44.

L. Norregaard and U. Gether: The monoamine neurotransmitter transporters: structure, conformational changes and molecular gating.
Curr Opin Drug Discov Dev (2001) 4, 591-601

43.

N. MacAulay, A. Bendahan, C. J. Loland,  T. Zeuthen, B. Kanner, and U. Gether: Engineered Zn2+ Switches in the GABA Transporter-1: Differential Effects on GABA Uptake and Currents.
J Biol Chem. (2001) 276, 40476-85

42.

R. Seifert, K. Wenzel-Seifert, U. Gether, B. K. Kobilka: Functional Differences between Full and Partial Agonists: Evidence for Ligand-Specific Receptor Conformations.
J Pharmacol Exp Ther (2001) 297,1218-26

41.

J. A. Ballesteros, A. D. Jensen, G. Liapakis, S.G.F. Rasmussen, L. shi, U. Gether, and J. Javitch:  Activation of the b2 adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6
J Biol Chem (2001) 276,29171-29177

40.

N. Boxenbaum, U. Gether, D. Klaerke and T. Zeuthen: Water transport by the glutamate EAAT-1 transporter.
J Physiol (2001) 530, 367-378

39.

A. D. Jensen, F. Guarnieri, S.G.F. Rasmussen, F. Asmar, J. Ballesteros, and U. Gether:  Mapping agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the ß2 adrenergic receptor by site-selective fluorescent labeling.
J Biol Chem (2001) 276, 9279-9290

38.

S.G.F. Rasmussen, A. D. Jensen, M.J. Maresch, I. Carroll, C. Tate, and U. Gether: Biophysical characterization of the cocaine binding pocket in the serotonin transporter using a fluorescent cocaine analogue as a molecular reporter.
J Biol Chem (2001) 276, 4717-4723

37.

L. Norregaard, Irache Visiers, Claus J. Loland, Juan Ballesteros, Harel Weinstein and U. Gether: Structural probing of a microdomain in the dopamine transporter by engineering of artificial Zn2+ binding sites.
Biochemistry (2000) 39:15836-46

36.

P. Ghanouni, H.T. Schambye, R. Seifert, T.W. Lee, U. Gether and B.K. Kobilka: Evidence for protonation in ß2 adrenergic receptor activation: The effect of pH on receptor function.
J Biol Chem (2000) 275, 3121-3127

35.

U. Gether: Uncovering Molecular Mechanisms Involved in Activation and inactivation of G Protein Coupled Receptors (disputats).
Endocrine Reviews (2000) 21, 90-113

34.

C.J. Loland, L. Norregaard and U. Gether: Defining proximity relationships in the tertiary structure of the dopamine transporter: identification of a conserved glutamic acid as a third coordinate in the endogenous zn2+ binding site.
J Biol Chem(1999) 274, 36928-36934

33.

R. Seifert R, U. Gether, K. Wenzel-Seifert, B.K Kobilka: Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations.
Mol Pharmacol (1999) 56, 348-358

32.

S.G.F. Rasmussen, A. Dam Jensen, P. Ghanouni, G. Liapakis, J. Javitch and U. Gether: Mutation of a conserved aspartic acid in the ß2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment VI.
Mol Pharmacol (1999) 56,175-84

31.

R. Seifert, K. Wenzel-Seifert, U. Gether, V.T. Lam and B.K. Kobilka: Examining the efficiency of receptor/G-protein coupling with a cleavable beta2-adrenoceptor-Gsalpha fusion protein.
Eur J Biochem. (1999) 260, 661-666

30.

B. K. Kobilka, U. Gether, R. Seifert, S. Lin and P. Ghanouni: Characterization of ligand-induced conformational states in the beta 2 adrenergic receptor.
J Recept Signal Transduct Res (1999) 19, 293-300

29.

L. Norregaard, D. Frederiksen, E. Ø. Nielsen, and U. Gether: Delineation of an endogenous zinc-binding site in the human dopamine transporter.
EMBO J (1998) 17, 4266-4273

28.

U. Gether and B. Kobilka: G protein-coupled receptors. II. Mechanism of agonist activation.
J Biol Chem (minireview) (1998) 273, 17979-17982

27.

B.K. Kobilka, U. Gether, R. Seifert, S. Lin, P. Ghanouni: Examination of ligand-induced conformational changes in the beta2 adrenergic receptor.
Life Sci (1998) 62, 1509-1512

26.

R Seifert, K. Wenzel-Seifert, T.W. Lee, U. Gether, E. Sanders-Bush, and B. Kobilka: Different effects of Gs,alpha splice variants on the ß2-adrenoceptor-mediated signalling: The ß2-adrenoceptor coupled to the long splice variant of Gs,alpha has properties of a constitutively active receptor.
J Biol Chem (1998) 273, 5109-5116

25.

B.K. Kobilka and U. Gether: Examination of ligand-induced conformational changes in the beta2-adrenergic receptor by fluorescence spectroscopy.
Adv Pharmacol (1998) 42, 470-473

24.

U. Gether, S. Lin, P.Ghanouni, J. Ballasteros, H. Weinstein and B.K.Kobilka: Agonists induce conformational changes in transmembrane segment III and VI of the ß2 adrenoceptor.
EMBO J (1997) 16, 6737-6747

23.

U. Gether, J. Ballasteros, R. Seifert, E. Sanders-Bush, H. Weinstein and B.K. Kobilka: Structural instability of a constitutively activated ß2 adrenergic receptor: Agonist-independent activation due to conformational flexibility.
J Biol Chem (1997) 272, 2587-2590

22.

S. Lin, U. Gether, and B. K. Kobilka: Ligand stabilization of the ß2 adrenergic receptor: Effect of DTT on receptor conformation monitored by circular dichroism and fluorescence spectroscopy.
Biochemistry (1996) 35, 14445-14451

21.

U. Gether, S. Lin and B.K. Kobilka: Fluorescent labeling of purified  ß2 adrenergic receptor: Evidence for ligand-specific conformational changes.
J Biol Chem (1995) 270, 28268-28275

20.

T.W. Schwartz, U. Gether, H.T. Schambye and S.A. Hjorth: Molecular mechanism of action of non-peptide ligands for peptide receptors.
Current Pharmaceutical Design (1995) 1, 325-342

19.

M.M. Rosenkilde, M. Cahir, U. Gether, S.A. Hjorth and T.W. Schwartz: Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding.
J Biol Chem (1994) 269, 28160-28164

18.

U. Gether, L. Nelson, J. A. Lowe III and T.W. Schwartz: Specific amino acid residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345.
J Biol Chem (1994)269, 23959-23964

17.

U. Gether, X. Emondsalt, J-C. Breliere, T. Fujii, D. Hagiwara, L. Pradier, C. Garret,T. E. Johansen and T.W. Schwartz: Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists on the NK-1 receptor.
Mol Pharmacol (1994) 45, 500-508

16.

C. J. Jensen, N.P. Gerard, T.W. Schwartz and U. Gether: The species selectivity of chemically distinct tachykinin nonpeptide antagonists are determined by common divergent residues of the rat and human neurokinin-1 receptors.
Mol Pharmacol (1994) 45, 294-299

15.

S. Zoffmann, U. Gether and T.W. Schwartz: Conserved HisVI-17 of the NK-1 receptor is involved in binding of nonpeptide antagonists but not substance P.
FEBS Letter (1993) 336, 506-510

14.

J. Dal Porto., T.E. Johansen, B. Catipovic, D.J. Parfiit, D. Tuveson, U. Gether, S. Kozlowski, D.T. Fearon and J. Schneck: A soluble class I major histo-compatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations.
Proc Natl. Acad Sci (U.S.A.) (1993) 90, 6671-6675

13.

U. Gether, Y. Yokota, X. Emonds-Alt, J-C. Breliere, J.A. Lowe III, R. M., Snider, S. Nakanishi and T.W. Schwartz: Two non-peptide tachykinin antagonists act through epitopes on corresponding segments of the NK-1 and NK-2 receptors
Proc Natl Acad. Sci (U.S.A.) (1993) 90, 6194-6198

12.

U. Gether, T.E. Johansen and T.W. Schwartz: Chimeric NK1 (substance P)/ NK3 (neurokinin B) receptors: Identification of domains determining the binding specificity of tachykinin agonists.
J Biol Chem (1993) 268, 7893-7898

11.

U. Gether, T.E. Johansen, R.M. Snider, J.A. Lowe III, S. Nakanishi & T.W. Schwartz: Different binding epitopes on the NK-1 receptor for substance P and a non-peptide antagonist.
Nature (1993) 362, 345-348

10.

B. S. Wulff, B. Catipovic, H. Okamoto, U. Gether, Schwartz, T. W. and T.E. Johansen: Efficient amidation of C-peptide deleted NPY precursors by non-endocrine cells is affected by the presence of Lys-Arg at the C-terminus.
Mol Cell Endocrinol (1993) 91, 135-141

9.

U. Gether, T. Marray, T.W. Schwartz and T.E. Johansen: Stable expression of high affinity NK1 (substance P) and NK2 (neurokinin A) receptors but low affinity NK3 (neurokinin B) receptors in transfected CHO cells.
FEBS Lett (1992) 296, 241-244

8.

D. Rønnov-Jessen, U. Gether and J. Fahrenkrug: PreproVIP derived peptides in tissue andplasma from patient with VIP-producing tumores.
Eur J Clin Invest (1991) 21, 154-160

7.

U. Gether, L.Aakerlund and T.W. Schwartz: Characterization of peptidyl-glycine-alfa-amidation activity in Medullary Thyroid Carcinoma cells, Pheochromocytomas and human serum.
Mol Cell Endocrinol (1991) 79, 53-63

6.

L. Aakerlund, U. Gether, J. Fuhlendorff, O. Thastrup, and T.W. Schwartz: Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase.
FEBS Lett (1990) 260, 73-78

5.

J.Fuhlendorff, U. Gether, L.Aakerlund, N.Langeland, H.Thøgersen, S.G. Melberg, O.Thastrup, U.B. Olsen & T.W.Schwartz: [Leu31,Pro34]Neuropeptide Y - a specific Y1- receptor agonist.
Proc Natl Acad Sci (U.S.A.) (1990) 87, 182-186

4.

U. Gether, H.V. Nielsen, and T.W. Schwartz: Tyrosylation and purification of peptides for radioiodination.
J Chromatography (1988) 447, 341-349

3.

T.W. Schwartz, H.F. Hansen, U. Gether and L. Aakerlund: Processing or inactivation of toad antimicrobial peptides.
Nature (1987) 329, 494, scientific correspondence.

2.

M.M.T. O'Hare, O. Tortora, U. Gether, H.V. Nielsen, and T.W. Schwartz: High-performance liquid chromatography of phenylthiocarbamyl derivatives of amino acids and side-chain derivatized amino acids.
J Chromatography (1987) 389, 379-388

1.

H.V. Nielsen, U. Gether and T.W. Schwartz: Cat pancreatic eicosapeptide and its biosynthetic intermediate.
Biochem J (1986) 240, 69-74

 

Book chapters, proceedings and other publications

19.

H. Bräuner-Osborne, M.M. Rosenkilde, U. Gether and D.E. Gloriam: G protein-coupled receptor pharmacology: the next generation.

Basic Clin Pharmacol Toxicol (2019) [Epub ahead of print]

18.

K. Brosen, U. Simonsen and U. Gether: Professor Arvid Carlsson (25 January 1923 to 29 June 2018) Obituary

Basic Clin Pharmacol Toxicol (2018) 123, 521-522

17.

C.J. Loland and U. Gether: ‘Neurotransmitter transporters: structure and function’ in ‘Texbook of Drug Design and Discovery’, 5th edition (eds.. U. Madsen, P. Krogsgaard-Larsen and K. Strømgaard), Taylor & Francis Group, LLC, 2015.

16.

U. Gether: ‘Serotonin og serotonerg farmakologi’ in ‘Basal og klinisk Farmakologi, 5th edition (eds. K. Brøsen, U. Simonsen, J.P. Kampmann and S. Thirstrup), FADL’s Forlag 2014

15.

M. Rathje, H. Fang, J.L. Bachman, V. Anggono, U. Gether, R.L. Huganir, K.L. Madsen: Reply to Wilkinson et al.: Concerning the use of pHluorin-tagged GluA2 as a reporter for NMDA-induced AMPA receptor recycling.
Proc Natl Acad Sci U S A (2014) 111, E305

14.

P.J. Hamilton, N.G. Campbell, S. Sharma, K. Erreger, F. Herborg Hansen, C. Saunders, A.N. Belovich, NIH ARRA Autism Sequencing Consortium, M.A. Sahai, E.H. Cook, U. Gether, H.S. McHaourab, H.J. Matthies, J.S. Sutcliffe and A. Galli: Drosophila melanogaster: a novel animal model for the behavioral characterization of autism-associated mutations in the dopamine transporter gene.
Mol Psychiatry (2013) 18,1235

13.

C.J. Loland and U. Gether: ‘Neurotransmitter transporters: structure and function’ in ‘Texbook of Drug Design and Discovery’, 4th edition (ed.. U. MAdsen), Taylor & Francis Group, LLC, 2009.

12.

S.G.F. Rasmussen and U. Gether: Molecular Mechanisms of GPCR Activation. G-Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity (eds. Roland Seifert, Thomas Wieland) in Methods and Principles of Medicinal Chemistry Vol. 24 (series eds. R.Mannhold, H.Kubinyi, and G.Folkers), Wiley Inc., 2005, pp. 27-42

11.

K. Nørgaard-Nielsen and U. Gether: Zn2+ modulation of neurotransmitter transporters.
Handb. Exp. Pharmacol. (2006) 175, 1-22

10.

C.J. Loland and U. Gether: Insights from endogenous and engineered Zn2+-binding sites in monoamine transporters. In Strategies of Molecular Neuropharmacology (eds. H. Brauner-Osborne and A. Schouboe) Humana Press, 2004

9.

S.G.F. Rasmussen and U. Gether: Structural basis for activation of G protein coupled receptors. In Structure and function of GPCRs in the nervous system (eds. M.N. Pangalos and C.H. Davies) Oxford Press, 2002.

8.

U. Gether, C.J. Loland and L. Norregaard: Delineating Structure-Function Relationships in the Dopamine Transporter from Natural and Engineered Zn2+ Binding Sites. In Proceedings of the 3rd International Symposium on Membrane Receptors, Signal Transduction and Drug Action, Yokohama 2000.
Life Science (2001) 68, 2187-98

7.

A. D. Jensen and U. Gether: Assessing adrenergic receptor using chemically reactive fluorescent probes. In Adrenergic Receptor Protocols, pp. 345-361 (ed. C. Machida) in the Methods for Molecular Biology (series ed. J. Walker), Humana Press Inc., 2000

6.

U. Gether and B.K Kobilka: Direct assessment of conformational changes in G protein coupled receptors using fluorescence spectroscopy. In Signal Transduction - A practical Approach, pp. 1-17 (ed. G. Milligan ) in the The practical Approach series, 2nd edition (series ed. B.D. Hames), Oxford University Press, Oxford 1999.

5.

U. Gether: Fluorescence spectroscopy analysis of conformational changes in the ß2 adrenergic receptor. In Structure/Function of G-protein coupled receptors, pp.315-334 (ed. J. Wess) in the Receptor Biochemistry and Methodology series (series eds D.R. Sibley and C.A. Strader), Wiley & Sons, New York 1999.

4.

U. Gether, S.Lin and B.K. Kobilka: Delineating ligand-specific structural changes in adrenergic receptors by use of fluorescence spectroscopy. In Proceedings of the ASPET Symposium, Alpha2-Adrenergic Receptors: Structure, Function and Therapeutic Implications, Satellite Symposium of the 9th International Conference on Second Messengers and Phosphoproteins, Nashville 1995, pages 31-43 (eds. S. Lanier and L. Limbird), Harwood Academic Publishers, Amsterdam 1997.

3.

B.K. Kobilka and U. Gether: Adrenergic Receptor Signal Transduction. In Structure and Function of 7TM receptors, Alfred Benzon Symposium 39, pages 171-179 (eds: T.W. Schwartz, S.A. Hjorth and J. Sandholm Kastrup) Munksgaard, Copenhagen 1995.

2.

U. Gether, J.A. Lowe III and T. W. Schwartz: Tachykinin non-peptide antagonists: binding domain and molecular mode of action.
Biochem. Soc. Trans. (1995) 23, 96-102

1.

U. Gether, T. E. Johansen, R. M. Snider, J. A. Lowe III, X. Emonds-Alt, Y. Yokota, S. Nakanishi and T.W. Schwartz: Binding epitopes for peptide and non-peptide antagonists on the NK-1 (substance P) receptor.
Regul. Peptides (1993) 46, 49-58

 

Patents 

3.

Inhibitors of PICK1 and uses thereof K. L. Madsen, K. Strømgaard, U Gether A. Bach, N. Riis Christensen
Application submitted Nov 2018 (EP18201731.9)

2.

K. L. Madsen, T.S. Thorsen, D. Peters, T. Dyhring, L.C. Rønn and U. Gether: PDZ domain modulators”
WO 2008148747 A8

1.

J. B. Jensen, L. S. Madsen, U. Gether and B.S. Jensen: Transporter arrays and methods and kits for producing and using the arrays.
WO 2002095064 A1